AIM Exploration Completes Comprehensive Report on Its Ability to Ship Coal Year-Round via the Port of Salaverry, Estimates Its Coal Capacity Shipments
Spotlight Companies Follow | Monday, 19 December 2016 12:56 (EST)Imports and Price of Anthracite at 23-Month High, AIM Exploration (OTCQB: AEXE) $AEXE Proceeds with its Project in Peru, Estimates Coal Capacity Shipments
HENDERSON, NV / ACCESSWIRE / December 19, 2016 / Attention, to our valued shareholders and investors and general coal industry audience:
As The Company progresses in preparation for extracting, transporting, and loading of coal, we wish to provide information to our valued investors of the strategic port of Salaverry, is located 17km from the city of Trujillo. Latitude -8º -9' -54' S, Longitude -79º 0' -38' W.
Its Cargo Pier water depth meets our demands for coal shipments at 31 - 35 feet (9.4 - 10 meters). Tide information is updated daily. Tug assist is on-ready, and quarantine stations with Deratt Cert (Ship sanitation certification) is present. Air, Radio, and Telephone communications are on-ready.
It is a major port and has met our potential client demands for Ship repairs, with refueling oil and diesel oil, water/provisioning/engine maintenance. Loading of the coal will be done in wharves and on-anchor. Mobile cranes and 24 ton Lists are available for AIM.
There are neither tide entrance restrictions nor overhead limits.
The Company has studied and consulted with its advisors, clients, and the port, and are pleased that the port is appropriate for year round loading and can provide year round shipping of coal. This efficiency allows the Company to provide coal in a cost effective, and nimble on-demand manner.
Coal supply chain approach is how the Company manages its availability. We are developing clear metrics highlighting our coal inventories at mines and the Port, the arrival date of vessels, the amount of coal being shipped from our mines. The port is ready for coal shipping; cargo shipping constitutes 42% of its monthly usage.
AIM is positioned to ship 2 to 4 shiploads of anthracite coal per month, currently the spot price exceeds $250.00 MT.
"Anthracite is necessary for steel and high-grade metal forging products. The prices currently range between $220 - $400USD per ton, and we have been monitoring the open-market prices, on sxcoal.com and alibaba.com, and they have been on the rise month over month. As the economy expands and with energy demands of G8 and emerging markets are unilaterally in line, we do not see this trend to plateau, rather it is continuing to put price pressure on un-replenishable energy resources," says JR Todhunter, President and CEO of AIM.
As of 2016-12-08 15:39:00 China Nov coal imports hit 23-month high of 26.97 million tonnes in November, up 24.96% from October. Figures and charts are available in image links or via our twitter account.
Please click or copy/paste on the links in this news releases for pictures of the port.
Comprehensive pictures and supplemental information is viewable upon opening the link to the PDF and Word document. Thank you.
About Aim Exploration:
The Company is an Anthracite coal mining and exploration company and plans to mine 1,000 hectares of land. We have expertise in business, mining, and legal with our distinguished board of directors and advisory board. We have amicable relationships with all parties involved in mining in Peru. We are a SEC reporting publicly traded company with the symbol (OTCQB: AEXE).
Forward-Looking Statements and Disclosures:
Certain information set forth in this press release contains "forward-looking statements" and "forward-looking information" under applicable securities laws. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements, which include management's assessment of future plans and operations and are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Some of the forward-looking statements may be identified by words such as "estimates," "expects," "anticipates," "believes," "projects," "plans," "targets," and similar expressions. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause AIM's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.
AIM Exploration Inc.
J.R. (Bob) Todhunter
Director, President & CEO
Twitter: www.twitter.com/aexeqb or @aexeqb
References and citations from external sources support this news release:
References #1: https://www.worldcoal.org/
References #2: https://www.searates.com
References #3: https://en.wikipedia.org/wiki/Bulk_carrier
References #4: http://www.sxcoal.com/site/index/en
Aim Exploration Completes Reports on its Ability to Ship Coal Year
In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer
CompaniesSymbolNamePriceChange%Volume FollowAEXEAim Exploration Inc0.010.0014.174,039,931
Premier Biomedical Pain Management Solutions Executives Advance Plans For An Array Of Opioid-Free New Products To Compete In $112 Billion Global Pain Market Beginning January, 2017
Posted at November 9, 2016 | By : Admin | Categories : Investor News,News,Press Releases | 0 CommentEL PASO, TX – November 9, 2016 – Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as non-narcotic, all-natural-ingredient, 50-state legal, novel pain management therapies, announced today that the management team from their Pain Management Division will attend an upcoming cannabis business conference & expo, November 15-18, 2016 in Las Vegas. This conference is the longest running, most respected cannabis industry conference, bringing together over 7500 cannabis industry leaders and over 300 exhibitors in one place.
William A. Hartman, President and CEO of Premier Biomedical, stated, “This is a tremendous opportunity for us to get a better picture of this growing segment of the all-natural-ingredient pain management industry, from scouting the competition, to benchmarking competitive products and establishing key contacts with suppliers, distributors, and potential customers. The experience gathered at this conference will also assist us in our on-going efforts to launch products to compete in the $112 billion global pain management market. Our initial product sales are slated to begin in just a few weeks, in January, 2017, with continuing multiple product launches throughout 2017. The products we will be launching include a 96-hour pain patch versus the competition at 6-12 hours, roll-ons, creams, sprays, lip balms and capsules.”
Ronald T. LaBorde, Managing Director of Premier’s Pain Management Solutions Joint Venture, said, “This is the premier event in the cannabis industry. Every serious player in the industry from growers, to manufacturers, to investors, to distributors and customers attend this event – a veritable Who’s Who of the industry. This conference comes at exactly the right time for us, as we are in the process of launching our global manufacturing and marketing strategies for our products.”
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, focusing on two major areas – 1) Biologics and Extracorporeal Treatments; and 2) Non-narcotic Pain Management Products. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending patents and provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
New York, NY., July 27, 2016 (GLOBE NEWSWIRE) -- Sparta Commercial Services, Inc. (OTCQB: SRCO), a leader in the development, management, and servicing of custom mobile applications for smartphones, reported that it will now offer subscription-based website development and management services to its mobile app customers.
Sparta’s CEO, Anthony Havens, said, “During two years of experiencing significant growth in our iMobileApp business, we have observed that many clients want and need improved website experiences for their customers. For many of our customers, content and technology upgrades are essential.”
With approximately 60% of internet traffic now on mobile or other non-desktop/laptop devices, one of the critical upgrades many websites need is mobile responsiveness. “Many customers want us to not only develop a mobile app, but also to convert their websites to the new mobile-friendly environment,” said Havens. “We believe that web development is a natural new business growth opportunity for us, and confident we are in the perfect position to provide that service to our customers.”
One example of this synergistic expansion of services is with hakalalabs.com – a mobile app customer and a web development client. Hakala Research’s Allyson Hakala, said, “iMobile Solutions developed a website for us with not only our business model in mind, but just as importantly, our clientele as well. We had immediate results and an uptick in online purchasing activity.”
Sparta Commercial’s iMobileApp videos available on YouTube
Watch our iMobileApp Restaurant, Grocery Store, and Entertainment videos available on YouTube:
iMobileApp Restaurant Video - https://www.youtube.com/embed/szYAwXtAiFg?VQ=HD1080
iMobileApp Grocery Store Video - https://www.youtube.com/embed/qz9Bs8qFj7o?VQ=HD1080
iMobileApp Entertainment Video - https://www.youtube.com/embed/RQ_NCICOhBE?vq=hd1080
To learn more about iMobileApp, please visit http://imobileapp.com/.
About Sparta Commercial Services, Inc.
Sparta Commercial Services, Inc. (OTCQB: SRCO) (http://spartacommercial.com/), through its subsidiary, iMobile Solutions, Inc., is a leader, in developing, managing, and servicing custom mobile apps for vehicle dealers from Harley-Davidson® to John Deere, automobiles and RVs, restaurants, liquor stores, clubs, and other businesses in 49 states and Canada. In addition to mobile apps, Sparta provides motor vehicle title history reports to dealers, insurance companies, credit unions, and consumers. The Company also offers vehicle and capital lease finance programs for municipalities.
iMobile Solutions, Inc. offers customizable mobile applications designed for vehicle dealers, providing for ongoing contact with their customers and communications of upcoming and ongoing promotions, special events, new and used inventory, and more, and for a wide range of other businesses and entities, offering a customized mobile app designed specifically for their purposes, at a fraction of the cost of both traditional and web marketing. iMobileApp, (http://imobileapp.com/), is a custom, fully-branded app that is an extension of a business’s e-presence. In addition, the company offers complete website design, development, hosting, support and maintenance.
The Company also provides detailed used vehicle title history reports to dealers, insurance companies, credit unions, etc., as well as to consumers. The reports are trusted by industry professionals to provide buyers accurate, timely, and thorough title history reports. The Company targets four motor vehicle markets through https://www.carvinreport.com/ (automobiles and light trucks), https://cyclechex.com/(motorcycles), https://www.rvchecks.com/ (recreational vehicles) and http://truckchex.com/ (commercial trucks).
Sparta's Municipal Leasing Division (http://spartamunicipal.com/) offers and administers a specialized municipal leasing program for local and state agencies. The Company is dedicated to serving jurisdictions with small and growing vehicle fleets who seek a better and more economical way to finance their essential equipment needs - from police motorcycles and cruisers, to EMS equipment and busses, to virtually any type of equipment a municipality requires. The Municipal Leasing Division also works with larger jurisdictions to provide competitive leasing facilities for specific segments of their fleet portfolio.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are valid only as of today and we disclaim any obligation to update this information. Actual results may differ significantly from management's expectations. These forward-looking statements involve risks and uncertainties that include, among others, risks related to potential future losses, competition, financing and commercial agreements and strategic alliances, seasonality, potential fluctuations in operating results and rate of growth, management of potential growth, system interruption, consumer and industry trends, limited operating history, and government regulation. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC, which are available on its website at: http://www.sec.gov.
Sandra L. Ahman
Sparta Commercial Services, Inc.
Copyright © 2016 GlobeNewswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Pre-Clinical Study to Determine Effectiveness of the Company's Immunotronics(TM) Platform in the Prevention of Heart Failure Following Myocardial InfarctionLOS ANGELES, CA -- (Marketwired) -- 12/19/16 -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the prevention of heart failure following myocardial infarction (MI). The pre-clinical study will evaluate the effect of the Company's non-invasive electroceutical technology on cardiac function, post-MI remodeling, and infarct size, as well as angiogenesis (the development of new blood vessels). The study, estimated to be complete at the end of the first quarter of 2017, represents the first of several planned studies designed to evaluate the Company's proprietary non-invasive electroceuticals in the treatment of vascular diseases and ischemia/reperfusion injury.
"We are leveraging the experience and proprietary knowledge of our scientific team, which has undertaken over 25 years of research and development in the field of bioelectromagnetic therapeutics in angiogenesis, neuroinflammation and ischemia to develop non-invasive treatments for substantially unmet clinical needs," commented Endonovo Chairman and CEO, Alan Collier
"A positive result in this study would represent a significant milestone for Endonovo and the field of bioelectronic medicine. We are moving to establish Endonovo as the leader in electroceuticals-based regenerative medicine. Our competitors in the bioelectronic medicine space are primarily developing implantable devices targeting the inflammatory response, and our competitors in regenerative medicine are developing cell therapies, biologics and gene therapies to treat many of these diseases, which are more expensive to develop and present significantly more safety concerns for potential patients.
"Our technology presents a lucrative opportunity to develop a non-invasive platform device that can be used to treat cardiovascular, cerebrovascular and peripheral artery disease as well as ischemia/reperfusion injuries," concluded Mr. Collier.
The Company had previously announced receiving a term sheet for $5 million in preferred financing from a strategic healthcare investor to develop a pipeline in vascular diseases, peripheral artery disease and ischemia/reperfusion injury. The $5 million proposed financing is part of a larger $15 million round of financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017.
About Heart Disease
Coronary artery disease (CAD) is the leading cause of death in the United States, with approximately 500,000 to 700,000 deaths related to CAD occurring each year.
In the United States, approximately 1.1 million cases of myocardial infarction (MI) occur annually, according to the American Heart Associations' Heart Disease and Stroke Statistics -- 2016 Update. MI is a condition where myocardial ischemia, a diminished blood supply to the heart, exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal operating function and homeostasis. Ischemia at this critical threshold level for an extended period results in irreversible myocardial cell damage or death, and can result in heart failure.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investors: Sign Up for Email Alerts on Endonovo
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Read more: http://www.nasdaq.com/press-release/endonovo-evaluating-therapeutic-potential-of-noninvasive-electroceutical-device-following-20161219-00409#ixzz4TzTMVtCE
Propanc Health Group Corp. (PPCH: OTCQB) | Propanc Commences GLP-Compliant 28-Day Repeat-Dose Toxicity Study
MELBOURNE, AUSTRALIA –(Marketwired – December 22, 2016) – Propanc Health Group Corporation (OTCQB: PPCH) („Propanc” or „the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced commencement of the in-life phase of the GLP-compliant, 28-day repeat-dose toxicity study for its lead product, PRP. PRP is a solution for once daily intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen.
The study is being conducted through the Company’s Partner CRO (Contract Research Organization), vivoPharm Pty Ltd, at their accredited laboratories in Melbourne, Australia. Data from the GLP (Good Laboratory Practice) compliant, 28-day repeat-dose toxicity study in rats will form the basis of a clinical trial application in the UK. Completion of the in-life phase is expected in February, 2017, with interim results reported in the first quarter of 2017.
Studies of this type are an important part of the development process for new therapeutic agents prior to clinical testing in humans and the study was discussed in detail at a recent scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, held earlier this year. Results from this study will help to provide a rationale to select a safe starting dose for first-in-man studies expected to commence in 2017.
In addition to the commencement of the GLP-compliant toxicity study, Propanc continues to work with its manufacturing partner, AmatsiQBiologicals, in Gent, Belgium, as it commences the detailed and technical process of preparing a suitable quality finished product for clinical trials. Activities include purification and characterization of the two pancreatic proenzymes, development and validation of analytical methods for quality assurance and stability testing of the final I.V. finished product formulation for PRP.
„We continue to remain solely focused on the development of PRP for our first-in-man studies. Once the 28 day study is completed, we will commence preparation of the clinical trial application in the UK. We are rapidly transforming into a clinical stage biopharmaceutical company, and are entering an exciting phase of development of PRP, a potential breakthrough for the treatment of metastatic cancer from solid tumors,” said James Nathanielsz, Propanc’s Chief Executive Officer.
To view Propanc’s „Mechanism of Action” video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc’s email distribution list, please email PPCH@kcsa.com with „Propanc” in the subject line.
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit:www.propanc.com.
All statements other than statements of historical fact contained herein are „forward-looking statements” for purposes of federal and state securities laws. Forward-looking statements may include the words „may,” „will,” „estimate,” „intend,” „continue,” „believe,” „expect,” „plan” or „anticipate” and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Post navigation← QS Energy, Inc. (QSEP: OTCQB) | QS Energy Issues Q4 Shareholder UpdateVega Biofuels, Inc. (VGPR: OTC Pink Current) | Vega Biofuels Release 12-22-16